Call for Papers  

Article Details

Review Article

The Current Status and Perspectives of Delivery Strategy for Boronbased Drugs

[ Vol. 26 , Issue. 26 ]


Zhu Yinghuai*, Xinglong Lin, Hongming Xie, Jianlin Li, Narayan S. Hosmane* and Yingjun Zhang *   Pages 5019 - 5035 ( 17 )


Boron-containing compounds are essential micronutrients for animals and plants despite their low-level natural occurrence. They can strengthen the cell walls of the plants and they play important role in supporting bone health. However, surprisingly, boron-containing compounds are seldom found in pharmaceutical drugs. In fact, there are no inherent disadvantages reported so far in terms of the incorporation of boron into medicines. Indeed, drugs based on boron-containing compounds, such as tavaborole (marked name Kerydin) and bortezomib (trade name Velcade) have been investigated and they are used in clinical treatment. In addition, following the advanced development of boron neutron capture therapy and a new emerging proton boron fusion therapy, more boron-containing medicinals are to be expected. This review discusses the current status and perspectives of delivery strategy for boron-containing drugs.


Boron, boron-containing compounds, boron-containing drugs, onychomycosis treatment, anti-cancer drugs, drug delivery, boron neutron capture therapy.


School of Pharmacy, Macau University of Science and Technology, Avenida Wai Long, Taipa 999078, Macau, New Drug Research Institute, HEC Pharma Group, Dongguan 523871, New Drug Research Institute, HEC Pharma Group, Dongguan 523871, HEC Research and Development Center, Dongguan 523871, Department of Chemistry and Biochemistry, Northern Illinois University, DeKalb, Illinois 60115-2862, New Drug Research Institute, HEC Pharma Group, Dongguan 523871

Read Full-Text article